Tirzepatide Research: The Dual GIP/GLP-1 Agonist and What Studies Have Investigated

What is tirzepatide (LY3298176)?

What is tirzepatide? It is a synthetic single-molecule peptide developed by Eli Lilly and known in the primary literature by its development code LY3298176. Its defining idea, as set out in the discovery paper, is that one engineered peptide was designed to act at two incretin receptors — the GIP receptor and the GLP-1 receptor — rather than one. It is the active molecule in the branded prescription products Mounjaro (approved for type 2 diabetes, 2022) and Zepbound (approved for chronic weight management, 2023); that is a factual identification of the molecule, made without any benefit framing, and its regulatory status is covered in its own section below.

The distinction to hold from the outset is that the material described here is a laboratory synthetic supplied as a lyophilized powder for bench work — not the marketed injectable medicine and not for human use. Everything below describes molecule properties and what published studies looked at.

Discovery and origin in the literature

Tirzepatide was introduced to the peer-reviewed literature by Coskun et al. (2018, Molecular Metabolism, PMID 30473097), the discovery-to-proof-of-concept paper that described the molecule’s design and receptor pharmacology. The engineering rationale, stated neutrally, was to combine incretin signalling from two receptors in a single long-acting peptide. That paper is the source for the molecule-design and receptor-activity descriptions on this page, and it marks tirzepatide as the dual-agonist member of the incretin-peptide class that Cellworks’ other GLP-class explainers also cover.

Reference data and molecule design

The molecule facts below are drawn from the discovery literature and the public chemical record (PubChem CID 156588324). Tirzepatide is a 39-residue peptide built on a GIP-based backbone, with several deliberate engineering features that the paper describes as conferring stability and a long circulating half-life.

Why those features matter (chemistry, not outcome)

Two design elements recur in the literature. The Aib substitution at position 2 confers resistance to dipeptidyl peptidase-4 (DPP-4), the enzyme that rapidly cleaves native incretins — a stability property. The C20 fatty-diacid chain enables reversible binding to circulating albumin, a common strategy for extending a peptide’s residence time in plasma. Consistent with that design, Schneck et al. (2024) reported a half-life of roughly five days, which the trials associated with a once-weekly schedule. These are descriptions of molecular chemistry and measured pharmacokinetics — not dosing guidance and not an effect a reader should expect.

Mechanism — the dual GIP/GLP-1 agonist

The tirzepatide mechanism described in the discovery pharmacology is agonism at two receptors by one molecule. Each line is framed as what researchers characterised in model systems, not as an effect in any reader:

• GIP receptor (GIPR) — the glucose-dependent insulinotropic polypeptide receptor. Because the backbone is GIP-based, Coskun et al. describe the molecule as engaging GIPR with high potency; this is the pathway that distinguishes it from the single GLP-1 agonists.
• GLP-1 receptor (GLP-1R) — the incretin and satiety-signalling receptor shared with the earlier single agonists in the class.
• Imbalanced dual activity — the discovery paper characterised the molecule’s activity as weighted between the two receptors rather than equal, a molecular-pharmacology observation reported in vitro.

The research rationale, stated neutrally, is that engaging both incretin receptors with a single molecule was studied as a way to combine their signalling within one investigational agent. That is a description of a scientific hypothesis under study — not a promise of any result. The three-molecule head-to-head across the incretin class — single vs dual vs triple — lives on the sibling comparison page; see Retatrutide vs Semaglutide vs Tirzepatide, which this page does not restate.

What the SURPASS and SURMOUNT trials investigated

Tirzepatide has an unusually large clinical-trial literature for a catalogue compound, organised into two named programs. Read strictly as what each study examined rather than as results a reader should expect:

Early-phase and SURPASS (type 2 diabetes)

• Frias et al., 2018 (Lancet, PMID 30293770) — the phase 2 dose-ranging trial of LY3298176 in people with type 2 diabetes; the study that carried the molecule from discovery into clinical investigation.
• Rosenstock et al., 2021 (Lancet, PMID 34186022) — SURPASS-1, a phase 3 monotherapy trial in type 2 diabetes.
• Frias et al., 2021 (NEJM, PMID 34170647) — SURPASS-2, which investigated tirzepatide against once-weekly semaglutide as the active comparator.
• Ludvik et al., 2021 (Lancet, PMID 34370970) — SURPASS-3, which investigated tirzepatide against insulin degludec on a metformin background.

SURMOUNT (obesity)

• Jastreboff et al., 2022 (NEJM, PMID 35658024) — SURMOUNT-1, a phase 3 trial that studied the molecule in adults with obesity; the anchor of the obesity program.

Each of these describes a specific study population and a set of measured variables; none is presented here with outcome figures, because the purpose of this page is to record what the trials investigated, not to translate their endpoints into expectations. The pharmacokinetics behind the once-weekly schedule were characterised separately by Schneck et al. (2024, PMID 38356317).

How tirzepatide differs from retatrutide (and the comparison page)

Because these molecules are frequently conflated, it is worth stating the differences plainly — as chemistry and status, not a ranking:

• Receptor count. Tirzepatide is a dual agonist (GIPR + GLP-1R). Retatrutide (LY3437943) is a triple agonist that adds the glucagon receptor (GCGR) as a third target.
• Regulatory status. Tirzepatide is an approved product (Mounjaro, Zepbound). Retatrutide is investigational and not approved by any regulator.
• Separate discovery papers. Tirzepatide comes from Coskun et al. 2018 (Molecular Metabolism); retatrutide from Coskun et al. 2022 (Cell Metabolism) — different molecules, different literatures.

For retatrutide’s own receptor pharmacology and trials, see Retatrutide research; for the side-by-side of receptor targets across the class, see Retatrutide vs Semaglutide vs Tirzepatide. This page focuses on tirzepatide’s own molecule and its own trials and hands off the cross-class comparison to those siblings rather than repeating it.

Regulatory status

To be explicit: tirzepatide is an approved prescription medicine — Mounjaro for type 2 diabetes (2022) and Zepbound for chronic weight management (2023). Those approvals are stated as a factual matter of record. The material offered here is not those medicines: it is supplied for laboratory research use only and is not for human or veterinary use. Nothing on this page is medical, efficacy or dosing guidance.

How to verify this compound yourself

For a 39-residue peptide, identity and purity are established by two orthogonal analytical methods, both reported on a per-batch Certificate of Analysis:

• HPLC purity — reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and reports purity as a percentage.
• Mass-spec identity — mass spectrometry confirms the measured mass against the expected molecular weight (≈ 4813 Da), an important check for a large peptide where deletions or truncations shift the mass.
• Endotoxin / sterility — where tested, separate quality attributes reported independently of chemical purity.

See how to read a COA for what each certificate line means and how to verify peptide purity for how HPLC and mass spec fit together. Check the exact batch on the self-serve verify tool.

Research-grade sourcing and verification

For laboratory research use only, tirzepatide is supplied with a per-batch Certificate of Analysis reporting HPLC purity (%) and mass-spectrometry identity confirmation. Because a mechanism summary is only as meaningful as the identity of the material behind it, the exact batch received can be checked directly on the verify tool. Logistics and verification only; nothing here is dosing or use guidance.

Frequently asked questions

Literature cited

1. Coskun T, Sloop KW, Loghin C, et al. “LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.” Mol Metab. 2018;18:3–14. PMID 30473097. pubmed.ncbi.nlm.nih.gov/30473097.
2. Frias JP, Nauck MA, Van J, et al. “Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a phase 2 trial.” Lancet. 2018;392(10160):2180–2193. PMID 30293770. pubmed.ncbi.nlm.nih.gov/30293770.
3. Rosenstock J, Wysham C, Frias JP, et al. “Tirzepatide in patients with type 2 diabetes (SURPASS-1): a phase 3 trial.” Lancet. 2021;398(10295):143–155. PMID 34186022. pubmed.ncbi.nlm.nih.gov/34186022.
4. Frias JP, Davies MJ, Rosenstock J, et al. “Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2).” N Engl J Med. 2021;385(6):503–515. PMID 34170647. pubmed.ncbi.nlm.nih.gov/34170647.
5. Ludvik B, Giorgino F, Jodar E, et al. “Once-weekly tirzepatide versus once-daily insulin degludec (SURPASS-3): a phase 3 trial.” Lancet. 2021;398(10300):583–598. PMID 34370970. pubmed.ncbi.nlm.nih.gov/34370970.
6. Jastreboff AM, Aronne LJ, Ahmad NN, et al. “Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1).” N Engl J Med. 2022;387(3):205–216. PMID 35658024. pubmed.ncbi.nlm.nih.gov/35658024.
7. Schneck K, Loghin C, Bhattacharya I, et al. “Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide.” CPT Pharmacometrics Syst Pharmacol. 2024;13(3):494–503. PMID 38356317. pubmed.ncbi.nlm.nih.gov/38356317.
8. Coskun T, Urva S, Roell WC, et al. “LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist… (retatrutide, for comparison).” Cell Metab. 2022;34(9):1234–1247. PMID 35985340. pubmed.ncbi.nlm.nih.gov/35985340.
9. National Center for Biotechnology Information. “PubChem Compound Summary for CID 156588324, Tirzepatide.” pubchem.ncbi.nlm.nih.gov/compound/156588324 (formula, mass, CAS 2023788-19-2).